Google
Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Does sickle cell disease increase risk of adverse outcomes following total hip and knee arthroplasty? A nationwide database study
source: The Journal of Arthroplasty
year: 2015
authors: Perfetti DC, Boylan MR, Naziri Q, Khanuja HS, Urban WP
summary/abstract:Sickle cell disease (SCD) is associated with impaired vascular function and progressive vaso-occlusive injury to bones. We used the Nationwide Inpatient Sample to identify all THA and TKA admissions between 1998 and 2010. After controlling for patient age, gender, insurance, race, and comorbidities, the risk of complication among admissions with SCD was 152% higher (P<0.001) for THA and 137% higher (P=0.001) for TKA. Patients with SCD had a length of stay that was 42% longer (P<0.001) for THA and 20% longer for TKA (P<0.001), and hospital charges that were 19% higher (P<0.001) for THA and 16% higher (P=0.001) for TKA. Orthopedic surgeons should counsel potential THA and TKA candidates with SCD of these risks prior to admission.
organization: SUNY Downstate Medical Center, Brooklyn; The Johns Hopkins University, BaltimoreDOI: 10.1016/j.arth.2014.10.035
read more full text
+myBinderRelated Content
-
Study Confirms Safe Use of Opioids for Pain Control in Sickle Cell DiseaseThe most common cause of hospital admiss...
-
Sickle cell gene linked to elevated risk of developing kidney failureNew research indicates that being born w...
-
Treating sickle cell disease: Is hydroxyurea right for you?Sickle cell disease changes the shape an...
-
CSL Behring to Acquire Biotech Company Calimmune and its Proprietary Stem Cell Gene Therapy PlatformGlobal biotherapeutics leader CSL Behrin...
-
Hydroxyurea Treatment for Sickle Cell Disease – Children’s National Health SystemAt Children’s National, we understand ...
-
Phase 1 trial to test under-the-skin injection of sevuparin in sickle cell patientsModus Therapeutics is going to launch ...
-
Preclinical Data on Proprietary AKT Inhibitor, ARQ 092, Demonstrating Effectiveness in the Treatment of Sickle Cell ...ArQule, Inc. (Nasdaq: ARQL) today announ...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.